Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Andrea Alfonso
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q1 (6 quarters; questions recorded in 4).
- Questions
- 7on tracked calls
- Challenge rate
- 0%none of 7 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 4with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 7 of 7 questions from 2 companies
ZTSZoetis5 questions · 4 reporting periods · 0 of 5 challenging
Calendar 2026 Q1
the 2% to 5% revenue growth outlook constant currency does not include any benefit from Neogen
Show response
Wetteny confirmed that the wider guidance range could accommodate the potential closing of the Neogen animal genomics acquisition within the stated 2-5% range.
how do you think about that trajectory and sort of frame the levers that you have at your disposal
Show response
Wetteny highlighted strong manufacturing execution with 140bp margin improvement ex-FX, though cautioned that livestock mix and geographic effects will influence trajectory.
Calendar 2025 Q4
does that sort of delay negate kind of the $30,000,000-plus that you saw in 4Q 2025 such that it is sort of a neutral impact?
Show response
Wetteny quantified the accounting timing impact at 30-40bps of 2025 total company revenue, immaterial to 3-5% growth range. Declined segment-level guidance but acknowledged easier H2 comps in US.
Calendar 2025 Q3
I would be curious if you could provide any color on the actual dosage share and debt clinics particularly among new puppies, did you retain or cede some share?
Show response
Wetteny confirmed share largely maintained at clinics. Triple combo share of prescribed oral medications grew from 30% to 47% over two years with substantial room to grow. Competitive share gains remain limited. Declined to discuss pricing spreads specifically but expressed confidence in product differentiation.
Calendar 2024 Q4
I specifically wanted to ask about the dermatology franchise and how you're thinking about your positioning in 2025 from a pricing versus mix standpoint
Show response
Kristin emphasized market expansion opportunity with 20M untreated dogs and noted Q4 delivered 11% derm growth despite competition. Wetteny highlighted balanced Cytopoint/Apoquel demand.
IDXXIdexx Laboratories2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2025 Q4
how do we think about your gross margin improvement stacking versus that 30 to 80 bps
Show response
Andrew noted Q4 delivered 60bps comparable gross margin expansion and 120bps operating margin improvement despite instrument mix pressure. For 2026, the 30-80bps comparable operating margin improvement expected to be largely gross-margin-led from recurring revenue growth, lab productivity, and high-margin cloud software expansion. Continued R&D and commercial investment in SG&A.
Calendar 2025 Q3
are you able to frame at all sort of how that sort of thinking in terms of just general cutoff points as far as age and frequency, where there's sort of agreeing on a sweet spot
Show response
Jay outlined two use cases: aid-in-diagnosis (currently bare majority) and wellness screening for dogs 7+ years or high-incidence breeds. Expects screening to become majority over time. Panel expansion to lymphoma + mast cell (>1/3 of canine cancers) plus a third biomarker in 2026 will make the value proposition increasingly compelling for wellness inclusion.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| ZTS Zoetis | 5 | 0%none of 5 questions |
| IDXX Idexx Laboratories | 2 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | No questions recorded | — | — |
| 2025 Q2 | No questions recorded | — | — |
| 2025 Q3 | 2 | 0%none of 2 questions | 2 |
| 2025 Q4 | 2 | 0%none of 2 questions | 2 |
| 2026 Q1 | 2 | 0%none of 2 questions | 1 |
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q1No questions recorded
- 2025 Q2No questions recorded
- 2025 Q32 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2025 Q42 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2026 Q12 questions · challenge rate 0% (none of 2 questions) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Guidance Reliability2
- Margin2
- Competitive Dynamics2
- Pricing2
- M&A1
- Cost Pressure1
- Capex Investment1
- Revenue Growth1
- Product Launch1
- Demand1